Division of Medical Safety Science, National Institute of Health Sciences, Kanagawa, Japan.
Department of Clinical Laboratory, Nagoya City University East Medical Centre, Nagoya, Japan.
J Pharmacol Sci. 2022 Oct;150(2):49-55. doi: 10.1016/j.jphs.2022.06.005. Epub 2022 Jul 31.
The coronavirus disease 2019 (COVID-19) pandemic has been associated with high mortality worldwide. Owing to its complicated pathophysiology, diagnostic and prognostic biomarkers for effective patient management remain scarce. We analyzed kynurenine, tryptophan, and serotonin levels in the serum of patients with COVID-19 via liquid chromatography/mass spectrometry analysis. Serum serotonin levels were decreased in patients with more severe COVID-19, along with increased kynurenine and decreased tryptophan concentrations. Patients with moderate disease who subsequently worsened showed significantly lower serotonin concentrations compared with those who did not experience severe disease. Serum serotonin levels may represent a valuable biomarker for COVID-19 severity and prognosis.
2019 年冠状病毒病（COVID-19）大流行在全球范围内导致了高死亡率。由于其复杂的病理生理学，有效的患者管理的诊断和预后生物标志物仍然稀缺。我们通过液相色谱/质谱分析分析了 COVID-19 患者血清中的犬尿氨酸、色氨酸和血清素水平。COVID-19 病情更严重的患者血清中的血清素水平降低，同时犬尿氨酸增加，色氨酸浓度降低。随后病情恶化的中度疾病患者的血清素浓度明显低于未发生严重疾病的患者。血清素水平可能是 COVID-19 严重程度和预后的有价值的生物标志物。
